Astellas continues to make deals, partnering with Adaptimmune 15-Jan-2020 By Ben Hargreaves The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.
Astellas acquires Xyphos and its CAR-T technology for $665m 09-Jan-2020 By Ben Hargreaves Astellas continues its acquisition spree in the advanced therapeutics space through a deal for Xyphos and its next-generation take on CAR-T therapies.
Pfizer eyes yield gains from doing gene therapy production in-house 09-Dec-2019 By Nick Taylor Pfizer tips $500m investment in gene therapy plant to improve yield, purity and characterization.
Astellas in $3bn gene therapy acquisition, highlights manufacturing capabilities 04-Dec-2019 By Ben Hargreaves Astellas agrees deal for Audentes, which has a pipeline of gene therapies and large-scale manufacturing capabilities.
Astellas taps into Pandion’s platform for bispecifics development 05-Nov-2019 By Vassia Barba Astellas and Pandion join forces to develop treatments for autoimmune pancreatic diseases using the latter’s modular immune effector.
Astellas provides funding for US cell and gene therapy biotechs 03-Oct-2019 By Ben Hargreaves Astellas to fund two biotech incubators, operated by LabCentral, to cultivate start-up companies focused on cell and gene therapies.
Hired and Retired: High profile exits to biotech 18-Jan-2019 By Ben Hargreaves The numbers of high profile executives departing large pharma companies this month again emphasised the draw of working in the biotech industry.
Astellas invests $256m in cell therapy manufacturing buildout 07-Nov-2018 By Ben Hargreaves The company will construct two facilities in Japan and relocate its regenerative medicine facility in the US.
Astellas prioritises ophthalmology with gene therapy acquisition 21-Aug-2018 By Ben Hargreaves Astellas has announced that it will acquire Quethera and its gene therapy programmes for the treatment of glaucoma.
